Cumberland Pharmaceuticals sharpens focus on rare disease pipeline with USD100m sale of branded US business to Apotex

Ipsen to acquire Memo Therapeutics to expand rare disease portfolio

Eurobio Scientific completes acquisition of CareDx's transplant lab products business

Aspen Neuroscience completes Cohort 3 and 4 dosing in Parkinson's disease trial

Will Therapeutics announces CQDM-backed research collaboration to improve treatment for anorexia nervosa and other compulsive disorders

Biohaven completes enrolment in opakalim RISE 3 epilepsy study

ADC Therapeutics completes enrolment in Phase 1b ZYNLONTA combination trial

Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease

Zelluna awarded NOK16m research grant for Phase 1 cancer study

AMR Clinical acquires ClinOhio Research Services

Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK

Viatris announces VR-205 Phase 3 Study results in Japanese adults with primary immunoglobulin A nephropathy

Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial

Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial

AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata